Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

Nov 18 2009

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.

Dr. Kate Cherry, MD, PhD, Head of the Neuropathy and Drug Toxicity Group at the Burnet Institute in Melbourne, Australia will share results of the Company's Phase IIa trial, entitled "Flupirtine as an adjunct to opioid analgesia in HIV neuropathy pain" during the Conference's Poster Session.